CUE Cue Biopharma Inc

$CUE Biotech trading poorly last 2 weeks with rates moving up…data w/in 30-45 days ;perhaps sooner…remain confident & continue to buy@these level$$$!!! The proof will be forthcoming & w/a small # of outstanding shares & the largest shareholders(my source) controlling & owning a majority of the shares in the float(haven’t sold) it comes down to the irrefutable law of supply and demand!

$CUE scooped up some shares @$26.80. Expecting this to bounce back on account of this dropping on no bad news.

$CUE with some data Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria "Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile"

B. Riley attributes $CUE selloff to missing IgE data and expected Week 36 fade, not weak efficacy. Aggressive buyer; $83 target.

$CUE to all the spaz traders who panic sold because they don't know how to read news or interpret data. Thank you... just the most heartfelt gratitude I pour out to you.

$CUE THEY ARE TAKING OUT WEAK-handed shareholders…plus… technically there was a superficial breach of the support line where people put Stop losses in and they clean them out too before driving the stock back up… data is coming, and my sources are extremely confident with the results… This is all on low volume cleaning up before it launches… Status quo and continued to nibble on stock & again; remain extremely confident!😎

$CUE there will be more data results shortly…The $50MM pipe was led by Cormorant and Threadneedle before the data. I would assume they would want to put more money in before the next data. They invested at $33 no warrants! Largest shareholders sold 0 shares…w/+data it goes to $60-70…(it was in $60’s pre-mkt last wk)… soon there after I believe a partnership or an outright acquisition! Continue to buy here & feeling extremely confident 😎

$CUE - clear dose response with signs of durability. Better than Xolair at all doses tested, delta & p-values in line... More to prove for sure, but a good first step

$CUE I thought that yesterday's action was a tell that an offering was imminent last night or this morning. But that didnt happen. With so many price targets above $60 and with a small float ( 6 millionish) I feel that sub 30 is a great entry price.

$CUE data seems well-differentiated against Xolair, esp at weeks 22 and beyond. I bought @ 25.75. GL longs.

$CUE bought and sold at $37, wasted 2 months on this shiistain stock, glad I broke even atleast. Went all in $PALI at $1.63

$CUE Strong science, promising clinical data, and a huge potential market. The current valuation doesn’t reflect the potential

$CUE keep your eyes peeled! This stock is seeing an increase in volume! $MI #momentum $FRGT #stockstotrade $AIXI #darkpoolai

If you like to find the runners early - Join the group of bulls below One of the best FREE small cap communities i know of 🔥 🫡💯 Couple bulls buying that $CUE / $PDSB spike

$CUE see this stock has a pattern I swung traded this 3 times with an average gain of 10%

$CUE Nasty - pumped to $65 and dumped into $26 lmao - feel like those silly china P&D that going up for weeks and one day they are like minus 80% without any reason lmao Missed this short

$CUE Covered my short from the $60.00's too soon but the low float could run again. Covered in the $56's.

$CUE Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint Cue Biopharma announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited. The trial enrolled 145 participants with moderate to severe chronic spontaneous urticaria, a disease resulting in chronic hives, that remained inadequately controlled despite treatment with H1 antihistamines. Key Highlights: Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile; Clinically different efficacy profile observed relative to XOLAIR highlights potential for a fundamental mechanism-based biological difference.

$CUE do not touch this stock , it’s labeled As a scam stock and will trash to $10-15 . Short it or short it on every dead cat bounce to make $$$$$$ lol in dead . Good luck all lmao$$

$CUE $44 short avg 1835 shares lmao I’m so so dead lol $$$ I’m sorry will take a week off and heading to golf soon ….. stay safe all. :)))))) mauhhh $$$$ haha